Senseonics Holdings, Inc. (SENS) earnings date

Nasdaq · Small cap · EDGAR filings

Email me when this date changes · free account, one click to stop

How this company behaves

Announces its report date Not enough announcements on file yet to say
Reports after the quarter ends 38 days, typically, give or take 11 (last 8 releases)

Last 8 releases

PeriodReleasedTimingDays after period endFiling
Q3 FY2026Mon, Nov 9, 2026after close 40 8-K
Q2 FY2026Thu, Aug 6, 2026after close 37 8-K
Q1 FY2026Thu, May 7, 2026after close 37 8-K
Q4 FY2025Mon, Mar 2, 2026after close 61 8-K
Q3 FY2025Wed, Nov 5, 2025after close 36 8-K
Q2 FY2025Wed, Aug 6, 2025after close 37 8-K
Q1 FY2025Thu, May 8, 2025after close 38 8-K
Q4 FY2024Mon, Mar 3, 2025after close 62 8-K

What they guided beta

Q3 FY2026 "Raised full-year 2026 revenue guidance to $68 million to $70 million from $62 million to $66 million, representing year-over-year growth of 93% to 98%" exhibit
Read from the sentence: revenue $68 million to $70 million, FY2026
Q3 FY2026 "Achieved gross margin of approximately 62% during Q3, and raising full-year gross margin guidance to more than 60% from 58% to 61% ​ GERMANTOWN, MD., November 9, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a diabetes company redefining continuous glucose monitoring (CGM) with long-term implantable sensing technology, today announced third quarter 2026 financial results and provided a business update." exhibit
Q3 FY2026 "Given the pace of U.S. outperformance, the Company now expects revenue outside the United States to represent approximately 15% of full-year 2026 revenue." exhibit
Q3 FY2026 "Full Year 2026 Financial Outlook Senseonics is raising its full-year 2026 global net revenue guidance to $68 million to $70 million from $62 million to $66 million, representing year-over-year growth of 93% to 98%, and is raising its full-year gross margin guidance to more than 60% from its prior range of 58% to 61%." exhibit
Q3 FY2026 "Forward Looking Statements Any statements in this press release about future expectations, plans and prospects for Senseonics, including the revenue and gross margin guidance under the heading “Full Year 2026 Financial Outlook” and expected geographic revenue mix; plans to expand the EON Care network and commercial outreach; anticipated benefits of commercial investments and initiatives; the continued roll-out of Eversense 365 in Europe; the anticipated timing and benefits of integrations with automated insulin delivery systems; future clinical development and intended functionality of Gemini " exhibit
Q2 FY2026 "Raising full-year 2026 revenue guidance to $62 million to $66 million from $60 million to $64 million, representing year-over-year growth of 76% to 87%" exhibit
Read from the sentence: revenue $62 million to $66 million, FY2026
Q2 FY2026 "Achieved gross margin of approximately 59% during Q2, and raising full-year gross margin guidance to a range of 58% to 61% from 55% to 58% GERMANTOWN, MD., August 6, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the design, development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced second quarter 2026 financial results and provided a business update." exhibit
Q2 FY2026 "Strengthened the balance sheet with the more than $100 million raised during Q2 — approximately $90 million in equity proceeds plus an expanded Hercules Capital facility of up to $140 million “This was the strongest quarter in Senseonics’ history, achieving record revenue and expanded margins, while integrating European commercial operations, building Eon Care, and advancing our Gemini and Freedom development programs,” said Tim Goodnow, PhD, President and Chief Executive Officer of Senseonics." exhibit
Q2 FY2026 "The Company expects this timing dynamic to normalize in the third and fourth quarters, with Europe still expected to represent approximately 20% of full-year revenue." exhibit
Q2 FY2026 "As of June 30, 2026, cash, restricted cash, and cash equivalents totaled $143.0 million, and outstanding indebtedness, including accrued interest, was $55.5 million, reflecting the more than $100 million raised in the second quarter through the equity offering and the amended Hercules Capital credit facility." exhibit

Get this as JSON

curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/SENS
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/SENS

Put this date on your page

A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.

Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.

SENS earnings date badge

HTML

<a href="https://veritasdata.dev/company/SENS/"><img src="https://veritasdata.dev/embed/SENS.svg" alt="SENS earnings date" width="240" height="56"></a>

Markdown

[![SENS earnings date](https://veritasdata.dev/embed/SENS.svg)](https://veritasdata.dev/company/SENS/)

Script

<script async src="https://veritasdata.dev/embed/SENS.js"></script>

Get a free key: 100 calls, every company

Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.

curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/SENS"

Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.